The development of denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), represents a novel approach to the prevention of fragility fractures in osteoporosis, skeletal complications of malignancy, and bone erosions in rheumatoid arthritis

Effects of denosumab on peripheral lymphocyte subpopulations

ROSSINI, Maurizio;VIAPIANA, Ombretta;ADAMI, Silvano;IDOLAZZI, Luca;GHELLERE, FRANCESCO;TRIPI, Gaia;ORTOLANI, RICCARDO;ZANOTTI, ROBERTA;GATTI, Davide
2016

Abstract

The development of denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), represents a novel approach to the prevention of fragility fractures in osteoporosis, skeletal complications of malignancy, and bone erosions in rheumatoid arthritis
denosumab, lymphocyte, rheumatoid arthritis
File in questo prodotto:
File Dimensione Formato  
Rossini et al denosumab Endocrine 2015 .pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 289.69 kB
Formato Adobe PDF
289.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/954017
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact